Skip to main content

Systemic strategies for prostate cancer.

Publication ,  Journal Article
Armstrong, AJ; Febbo, PG; George, DJ; Moul, J
Published in: Minerva Urol Nefrol
March 2007

Systemic therapy beyond hormonal therapy for advanced prostate cancer includes chemotherapy, antiangiogenic therapy, signal transduction inhibitors, immunomodulatory therapy, and other experimental therapeutics. This review will discuss the state of systemic therapy for advanced prostate cancer in 2007, with an emphasis on therapy in the neoadjuvant, adjuvant, and metastatic setting. As chemotherapy gains greater acceptance in the urologic oncology community for use in men with hormone-refractory disease, evaluating the role of systemic therapy in earlier disease states is essential given the success in other solid tumors for advancing cure rates. Current randomized phase III trials worldwide are addressing these questions in each disease state, and are anticipated to change the landscape of prostate cancer management for years to come. In this discussion, we will emphasize those agents that are currently being evaluated in phase II and III trials, with an emphasis on those trials that are likely to impact the standard of care in the near future. The collection of tumor or surrogate tissue is emphasized to define biomarkers that may predict for sensitivity to these systemic therapies.

Duke Scholars

Published In

Minerva Urol Nefrol

ISSN

0393-2249

Publication Date

March 2007

Volume

59

Issue

1

Start / End Page

11 / 25

Location

Italy

Related Subject Headings

  • Urology & Nephrology
  • Treatment Failure
  • Prostatic Neoplasms
  • Male
  • Immunotherapy
  • Humans
  • Combined Modality Therapy
  • Antineoplastic Agents, Hormonal
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Armstrong, A. J., Febbo, P. G., George, D. J., & Moul, J. (2007). Systemic strategies for prostate cancer. Minerva Urol Nefrol, 59(1), 11–25.
Armstrong, A. J., P. G. Febbo, D. J. George, and J. Moul. “Systemic strategies for prostate cancer.Minerva Urol Nefrol 59, no. 1 (March 2007): 11–25.
Armstrong AJ, Febbo PG, George DJ, Moul J. Systemic strategies for prostate cancer. Minerva Urol Nefrol. 2007 Mar;59(1):11–25.
Armstrong, A. J., et al. “Systemic strategies for prostate cancer.Minerva Urol Nefrol, vol. 59, no. 1, Mar. 2007, pp. 11–25.
Armstrong AJ, Febbo PG, George DJ, Moul J. Systemic strategies for prostate cancer. Minerva Urol Nefrol. 2007 Mar;59(1):11–25.

Published In

Minerva Urol Nefrol

ISSN

0393-2249

Publication Date

March 2007

Volume

59

Issue

1

Start / End Page

11 / 25

Location

Italy

Related Subject Headings

  • Urology & Nephrology
  • Treatment Failure
  • Prostatic Neoplasms
  • Male
  • Immunotherapy
  • Humans
  • Combined Modality Therapy
  • Antineoplastic Agents, Hormonal